Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
13-valent Pneumococcal Conjugate Vaccine (PCV13)
9%
30-day Mortality
6%
Amoxicillin-clavulanate
7%
Antibiotic Resistance
10%
Antibiotic Treatment
9%
Antibiotic Use
10%
Antibiotics
11%
Bacteremia
13%
BNT162b2
8%
BNT162b2 Vaccine
6%
Clinical Characteristics
8%
Comorbidity
6%
Confidence Interval
14%
COVID-19
19%
Empirical Therapy
6%
Encephalitis
6%
Escherichia Coli
9%
Ethiopian
7%
Fourth Dose
6%
Highly Active Antiretroviral Therapy (HAART)
6%
HIV Patients
20%
HIV-1 Subtype C
7%
HIV-positive
7%
Hospital Admission
9%
Hospitalization
7%
Hospitalized Patients
18%
Human Immunodeficiency Virus Type 1 (HIV-1)
33%
Infected Patients
7%
Invasive Pneumococcal Disease
11%
Israel
100%
Israeli
23%
Men Who Have Sex with Men
6%
Methicillin-resistant Staphylococcus Aureus
17%
Nationwide Surveillance
9%
Odds Ratio
20%
Older Adults
6%
Oncology Patients
6%
Quinolones
10%
Randomized Controlled Trial
6%
Retrospective Cohort Study
6%
Risk Behavior
8%
Risk Factors
17%
Surgical Site Infection
8%
Surveillance Studies
6%
Vaccination
7%
Viral Load
9%
Virological Failure
6%
Virus
11%
West Nile Fever
14%
West Nile Virus Infection
6%
Pharmacology, Toxicology and Pharmaceutical Science
2009 H1N1 Influenza
5%
Amoxicillin
8%
Antibiotic Therapy
5%
Antibiotics
9%
Antiinfective Agent
13%
Antimicrobial Resistance
6%
Aztreonam
5%
Bloodstream Infection
25%
Ciprofloxacin
6%
Clavulanic Acid
8%
Cohort Study
23%
Combination Therapy
5%
Coronavirinae
5%
Diseases
21%
Enterobacteriaceae
5%
Escherichia coli
5%
Gentamicin
5%
Hematologic Malignancy
6%
HIV
27%
Infection
26%
Methicillin-Resistant Staphylococcus Aureus
9%
Mortality Rate
5%
Penicillin
6%
Piperacillin Plus Tazobactam
5%
Pneumococcal Infection
11%
Pneumococcus Vaccine
6%
Pneumocystis Jiroveci
5%
Prevalence
8%
Quinolone
5%
Quinolone Derivative
12%
Randomized Controlled Trial
7%
Retrospective Study
5%
Rituximab
8%
SARS Coronavirus
8%
Streptococcus pneumonia
6%
West Nile Fever
8%
Medicine and Dentistry
Antibiotic Therapy
9%
Antiretroviral Therapy
8%
Bloodstream Infection
16%
Cohort Analysis
13%
Combination Therapy
5%
Comorbidity
5%
COVID-19
15%
Cross Sectional Study
5%
Diseases
11%
Drug Resistance
12%
Encephalitis
5%
Enterobacteriaceae
5%
Extended Spectrum Beta Lactamase
5%
Hematologic Malignancy
5%
High Risk Behavior
5%
Human Immunodeficiency Virus
41%
Human Immunodeficiency Virus Infection
5%
Infection
17%
Mortality Rate
8%
Nonnucleoside Reverse Transcriptase Inhibitor
5%
Odds Ratio
7%
Omicron Coronavirus Variant
7%
Pneumococcal Infection
8%
Pneumocystis Jirovecii
5%
Prevalence
8%
Resistance Mutation
6%
Rituximab
8%
Serotype
5%
Severe Acute Respiratory Syndrome Coronavirus 2
12%
Surgical Infection
8%
Virus
6%
Virus Infection
7%
West Nile Fever
11%
West Nile Virus
8%
